Product Description
Argipressin is a synthetic peptide identical to the endogenous nonapeptide hormone with antidiuretic property. Synthesized in the hypothalamus and stored/released from the posterior lobe of the pituitary, argipressin's primary function is regulating extracellular fluid volume. This agent can also act as a vasoconstrictor, increasing blood pressure and systemic vascular resistance. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Argipressin)
Mechanisms of Action: AVP Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Belgium | Bulgaria | Canada | Colombia | Czech | Denmark | Dominican Republic | Ecuador | Estonia | Finland | France | Germany | Greece | Hungary | Indonesia | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Arab Emirates | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Anne Ristikankare
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CORVaso | P2 |
Completed |
Unknown |
2022-08-02 |